These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15073130)

  • 41. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
    Haddad R; Colevas AD; Krane JF; Cooper D; Glisson B; Amrein PC; Weeks L; Costello R; Posner M
    Oral Oncol; 2003 Oct; 39(7):724-7. PubMed ID: 12907212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
    Wen XF; Yang G; Mao W; Thornton A; Liu J; Bast RC; Le XF
    Oncogene; 2006 Nov; 25(52):6986-96. PubMed ID: 16715132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
    Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
    Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
    Aoyama K; Kamio T; Nishikawa T; Kameoka S
    Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.
    Kim H; Danishmalik SN; Hwang H; Sin JI; Oh J; Cho Y; Lee H; Jeong M; Kim SH; Hong HJ
    Cancer Gene Ther; 2016 Oct; 23(10):341-347. PubMed ID: 27632934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.
    Dennis MS; Jin H; Dugger D; Yang R; McFarland L; Ogasawara A; Williams S; Cole MJ; Ross S; Schwall R
    Cancer Res; 2007 Jan; 67(1):254-61. PubMed ID: 17210705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. From HER2 to herceptin.
    Mokbel K; Hassanally D
    Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice.
    Tomblyn S; Springs AE; Langenheim JF; Chen WY
    Int J Oncol; 2009 Apr; 34(4):1139-46. PubMed ID: 19287973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression.
    Hardy S; Wong NN; Muller WJ; Park M; Tremblay ML
    Cancer Res; 2010 Nov; 70(21):8959-67. PubMed ID: 20841483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiogenic acceleration of Neu induced mammary tumor progression and metastasis.
    Oshima RG; Lesperance J; Munoz V; Hebbard L; Ranscht B; Sharan N; Muller WJ; Hauser CA; Cardiff RD
    Cancer Res; 2004 Jan; 64(1):169-79. PubMed ID: 14729621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.
    Müller-Decker K; Berger I; Ackermann K; Ehemann V; Zoubova S; Aulmann S; Pyerin W; Fürstenberger G
    Am J Pathol; 2005 Feb; 166(2):575-84. PubMed ID: 15681840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    BioDrugs; 2006; 20(4):259-62. PubMed ID: 16831025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
    Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
    Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Examination of tumour histopathology and gene expression in a neu/S100A4 transgenic model of metastatic breast cancer.
    Simpson PT; Shoker BS; Barraclough R; Halliwell N; Rudland PS; Sibson DR; Davies MP
    Int J Exp Pathol; 2003 Aug; 84(4):173-84. PubMed ID: 14632631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
    Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
    Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.